A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Clinical trial NCT07330544 · RECRUITING
Trial details
- NCT number
- NCT07330544
- Sponsor
- Zhejiang Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-24
- Primary completion
- 2027-11-25
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.